![Kenneth Cundy](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kenneth Cundy
Chief Tech/Sci/R&D Officer at
ANEBULO PHARMACEUTICALS, INC.
Net worth: - $ as of 31/07/2026
Profile
Kenneth C.
Cundy currently works at Anebulo Pharmaceuticals, Inc., as Chief Scientific Officer from 2022.
Dr. Cundy also formerly worked at Gilead Sciences, Inc., as Senior Director-Biopharmaceutics from 1992 to 2000, CohBar, Inc., as Chief Scientific Officer from 2014 to 2022, and XenoPort, Inc., as Chief Scientific Officer from 2012 to 2014.
Dr. Cundy received his undergraduate degree from The University of Manchester and doctorate degree from the University of Kentucky.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 26/09/2025 | 0 ( -.--% ) | - $ | 31/07/2026 |
Kenneth Cundy active positions
| Companies | Position | Start |
|---|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 20/05/2022 |
Former positions of Kenneth Cundy
| Companies | Position | End |
|---|---|---|
| COHBAR | Chief Tech/Sci/R&D Officer | 31/03/2022 |
| XENOPORT, INC. | Corporate Officer/Principal | 01/11/2014 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/01/2000 |
Training of Kenneth Cundy
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
55
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Gilead Sciences, Inc.
 Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
CohBar, Inc.
 CohBar, Inc. BiotechnologyHealth Technology Develops biotechnology products that intends to treat age-related diseases through the discovery of novel mitochondrial-derived peptides | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing of pharmaceutical products for the potential treatment of neurological disorders | Health Technology |
University of Kentucky
 University of Kentucky Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anebulo Pharmaceuticals, Inc.
 Anebulo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
- Stock Market
- Insiders
- Kenneth Cundy
